Over a single decade, the number of Australian women receiving intravenous iron infusions grew seventeen times over — a shift that speaks both to a long-overdue reckoning with iron deficiency's toll on women's lives and to the uneven terrain on which medical progress tends to unfold. By 2024, one in twenty women of reproductive age had received the treatment, and public spending had climbed from $1.1 million to more than $82 million. Researchers now ask whether this surge reflects genuine progress in care or whether it quietly encodes new inequities — in geography, in cost, and in who is able
IV Iron Use Among Australian Women Surges 17-Fold in Decade
Iron deficiency causes debilitating fatigue, poor concentration, and reduced quality of life; treatment completion barriers may leave women undertreated.
Some women may not be receiving the full benefit of treatment
Mark
Why did intravenous iron use jump so dramatically in just a decade?
Mimi
The researchers point to growing awareness of how iron deficiency actually affects women's lives—the fatigue, the cognitive fog, the physical decline. But it's also partly about the treatment itself becoming more accessible. Newer formulations like ferric carboxymaltose are easier to administer, and GPs started prescribing it, not just specialists.
Mark
So more awareness and easier access. But what about the women who don't finish their treatment?
Mimi
That's the troubling part. One in four women stop before completing their prescribed course. Some feel better after the first infusion and assume they're done. Others can't afford the next one—clinics charge hundreds of dollars per visit. We don't fully know yet, but cost is almost certainly a factor.
Mark
The geographic variation is striking—some regions use it three times more than others. What explains that?
Mimi
That's what the researchers want to understand better. It could be clinical practice differences, but cost barriers likely play a role. If you live in a region where fewer clinics offer the treatment, or where out-of-pocket costs are higher, you're less likely to access it. Concession card status matters too—your economic circumstances shape whether you can afford the treatment.
Mark
Is intravenous iron being overused, then?
Mimi
The researchers are careful here. They say it's generally safe and effective, but it's meant for specific situations—when oral iron fails, can't be tolerated, or when you need rapid replacement. The question isn't whether it's overused overall, but whether it's being used equitably. Some women get it; others don't, for reasons that may have nothing to do with medical need.
Mark
What happens to women who need it but can't access it or afford to finish?
Mimi
They stay iron deficient. They live with the fatigue, the concentration problems, the reduced capacity to work or care for their families. It's a quality-of-life issue that becomes invisible once you stop counting the prescriptions.
Le Pouls
- Iron deficiency quietly diminishes the lives of vast numbers of women — through exhaustion, lost concentration, and reduced capacity — yet for a decade it went dramatically undertreated.
- A seventeen-fold rise in intravenous iron prescriptions signals a medical culture finally taking women's chronic conditions seriously, but the speed of that shift has outpaced the systems meant to support it.
- Nearly one in four women prescribed the treatment never completes it, leaving bodies still depleted — whether from the cost of infusions running into hundreds of dollars, or from a false sense of recovery after the first dose.
- Some regions of Australia use intravenous iron at rates three times higher than others, exposing fault lines of geography, income, and access that no surge in prescriptions alone can heal.
- Researchers are now calling for evidence-based protocols and a clear-eyed investigation into who is falling through the gaps — before a treatment success story quietly becomes a story of stratified care.
Over a single decade, the number of Australian women receiving intravenous iron infusions grew seventeen times over — a shift that speaks both to a long-overdue reckoning with iron deficiency's toll on women's lives and to the uneven terrain on which medical progress tends to unfold. By 2024, one in twenty women of reproductive age had received the treatment, and public spending had climbed from $1.1 million to more than $82 million. Researchers now ask whether this surge reflects genuine progress in care or whether it quietly encodes new inequities — in geography, in cost, and in who is able to see a course of treatment through to its end.
Between 2013 and 2024, the number of Australian women receiving intravenous iron infusions grew seventeen times over. By last year, one in twenty women of reproductive age had received the treatment, and spending — by government and patients combined — had climbed from $1.1 million to more than $82 million.
Researchers at Flinders University and SAHMRI spent a decade examining pharmaceutical data and found a picture that is both encouraging and unsettling. Iron deficiency is among the most common health burdens women carry through their reproductive years. Menstrual blood loss, pregnancy, and breastfeeding steadily deplete the body's iron stores, and when oral supplements fail or cannot be tolerated, intravenous iron offers a faster route to recovery — easing the fatigue, poor concentration, and diminished quality of life that deficiency brings.
Yet the surge carries complications. Almost one in four women prescribed the treatment never completed their full course. Some stopped after feeling better following an initial infusion. Others faced out-of-pocket costs of hundreds of dollars per session that made continuation difficult. The result is that many women may be receiving less iron replacement than their bodies actually need.
The landscape of prescribing has also shifted. A newer formulation, ferric carboxymaltose, now accounts for nearly 94 percent of prescriptions, and general practitioners — rather than specialists — write more than 60 percent of them. That democratization of access has likely driven much of the increase, though it also raises questions about consistency of care across different settings.
Geographic disparities add another layer of concern. Some parts of Australia use intravenous iron at rates more than three times higher than others, with variations tied to where women live, their age, and their socioeconomic status. Lead researcher Dr. Gizat Kassie points to cost as a likely factor in these gaps. Associate Professor Luke Grzeskowiak frames the overall rise as evidence of growing awareness about iron deficiency's real impact on women's health — but both researchers stress that the expansion demands scrutiny. The central question, they argue, is whether this growth reflects better clinical practice or whether it masks inequities in access, affordability, and follow-through that leave too many women still undertreated.
Between 2013 and 2024, the number of Australian women receiving intravenous iron infusions grew seventeen times over. By last year, one in every twenty women of reproductive age—roughly five per hundred—had received the treatment. The shift is stark when you look at the money: government and patient spending on intravenous iron alone climbed from $1.1 million to more than $82 million across that same decade.
Researchers at Flinders University and SAHMRI analyzed a decade of pharmaceutical data and found something worth examining closely. Iron deficiency remains one of the most common health problems women face during their reproductive years. Menstrual bleeding, pregnancy, childbirth, and breastfeeding all drain the body's iron stores. Without treatment, the consequences are real: debilitating fatigue, difficulty concentrating, reduced physical capacity, a measurable decline in quality of life. For women whose bodies cannot absorb oral iron tablets or who experience intolerable side effects from them, intravenous iron offers a faster path to replenishment.
Yet the surge raises questions. Almost one in four women prescribed intravenous iron never completed their full course of treatment. The reasons remain unclear. Some women report feeling better after an initial infusion and stop. Others face financial barriers—clinics charge hundreds of dollars per infusion, and out-of-pocket costs accumulate quickly. The incomplete treatment picture suggests some women may be receiving less iron replacement than their bodies need.
The type of intravenous iron being used has also shifted dramatically. Ferric carboxymaltose, a newer formulation, now accounts for nearly 94 percent of all prescriptions. General practitioners, rather than specialists, now write more than 60 percent of the prescriptions. This democratization of access has likely contributed to the overall increase, though it also raises questions about consistency of care.
Geographic disparities tell another story. Some parts of Australia use intravenous iron at rates more than three times higher than others. These differences correlate with where women live, their age, whether they hold a concession card, and who prescribes their treatment. Dr. Gizat Kassie, lead author of the study, notes that cost likely plays a role in these variations. For some women, the out-of-pocket expense becomes a barrier to starting treatment or completing it. The researchers emphasize that while intravenous iron is generally safe and effective, it is typically recommended only when oral iron has failed, cannot be tolerated, or when rapid iron replacement is medically necessary.
Associate Professor Luke Grzeskowiak frames the increase as evidence of growing awareness about iron deficiency's impact on women's health. The treatment can make a tangible difference in daily functioning. But the researchers also stress that the surge demands scrutiny. They call for a clearer understanding of what drives the geographic and socioeconomic variations, and whether all women are receiving equitable access to the most appropriate care. The question now is whether this expansion of treatment reflects better clinical practice or whether it reflects gaps in access, affordability, and follow-through that leave some women undertreated.
Citations marquantes
Iron deficiency can have a significant impact on women's health and wellbeing, but it is treatable. Our findings show that intravenous iron has become an increasingly important part of care for Australian women, and we need to make sure its use remains evidence-based, effective and equitable.— Associate Professor Luke Grzeskowiak, Flinders University
We need to better understand what is driving these differences and whether all women are receiving equitable access to the most appropriate treatment. Some of the variation may reflect differences in clinical practice, but cost could also be playing a role.— Dr. Gizat Kassie, SAHMRI
Envie de l'histoire complète ?
Lire l'original sur News-Medical ↗
Health & Medicine